Yes, nortriptyline is absolutely contraindicated in patients with active or recent coronary artery disease.
Nortriptyline is explicitly contraindicated during the acute recovery period after myocardial infarction 1. This is a black-box contraindication from the FDA drug label that takes precedence over all other considerations.
Clear Contraindication Framework
The FDA label for nortriptyline provides an unequivocal contraindication: patients in the acute recovery period after myocardial infarction should not receive this medication 1. This represents the highest level of regulatory warning and must be strictly observed.
Defining "Active or Recent" CAD
Acute recovery period after MI: Absolutely contraindicated 1
Recent MI (within weeks to months): The evidence strongly suggests avoiding nortriptyline:
- In one geriatric case series, acute myocardial infarction developed after just two 10-mg doses of nortriptyline 2
- Tricyclic antidepressants (TCAs) including nortriptyline are associated with increased mortality in CAD patients, with a hazard ratio of 1.74 (95% CI 1.12-2.69) 3
Stable CAD with prior MI: Still contraindicated based on the mortality data and cardiovascular effects detailed below.
Why This Contraindication Exists: The Cardiovascular Toxicity Profile
Autonomic Dysfunction
Nortriptyline causes significant autonomic impairment that directly increases cardiac risk 3:
- Reduced heart rate variability - a known predictor of sudden cardiac death
- Elevated norepinephrine levels - increasing myocardial oxygen demand
- These autonomic effects mediate the increased mortality seen with TCA use in CAD patients 3
Direct Cardiac Effects
The cardiovascular toxicity is substantial and dose-dependent 4, 5:
- Sustained tachycardia: 11% increase in heart rate (from 75 to 83 bpm) 4
- Conduction abnormalities: Prolonged PQ interval, QRS widening, and QTc prolongation 6
- Arrhythmias: Including bundle branch blocks and ventricular arrhythmias 2
- Orthostatic hypotension: Leading to falls and syncope 5
Clinical Outcomes Data
A head-to-head comparison trial demonstrated the danger clearly 4:
- Adverse cardiac events: 18% with nortriptyline vs. 2% with paroxetine (p<0.03)
- Both drugs were equally effective for depression, but nortriptyline carried 9-fold higher cardiac event rate
- In long-term follow-up, 52.3% of TCA users died compared to 37.3% of non-users 3
What to Use Instead
For depression in CAD patients, the evidence-based alternatives are:
SSRIs (particularly sertraline or paroxetine): Safe and effective in CAD patients 4. Sertraline was specifically studied in post-ACS patients and found safe 7
Cognitive behavioral therapy: Effective without cardiovascular risk 7
If antidepressant needed: Paroxetine showed equivalent antidepressant efficacy to nortriptyline but with only 2% adverse cardiac events vs. 18% 4
Critical Pitfall to Avoid
Do not rationalize using "low doses" of nortriptyline in CAD patients. Even minimal exposure has caused acute MI 2, and the cardiovascular effects are present at therapeutic doses 4, 6. The nortriptyline metabolite specifically drives the cardiac toxicity through conduction system effects and autonomic dysfunction 6.
Guideline Context
While depression treatment guidelines for CAD patients 7, 8 acknowledge the importance of treating depression to improve outcomes, they consistently recommend against TCAs. The 2013 ACC/AHA UA/NSTEMI guidelines 7 note that sertraline was safe and effective for depression post-ACS, establishing the precedent for SSRI use rather than TCAs in this population.
The bottom line: Nortriptyline should never be prescribed to patients with active or recent coronary artery disease. The FDA contraindication, mortality data, and availability of safer alternatives make this an absolute prohibition in clinical practice.